Notice2026-07335
Increasing Access to Nonprescription Drugs; Public Meeting; Request for Comments
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 15, 2026
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA, the Agency, or we) is announcing a public meeting entitled "Increasing Access to Nonprescription Drugs." The purpose of the public meeting is to discuss perspectives from interested parties on increasing access to nonprescription drugs. We are also requesting comments.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 72 (Wednesday, April 15, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 72 (Wednesday, April 15, 2026)]
[Notices]
[Pages 20170-20171]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-07335]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2025-N-4731]
Increasing Access to Nonprescription Drugs; Public Meeting;
Request for Comments
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting; request for comments.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is
announcing a public meeting entitled ``Increasing Access to
Nonprescription Drugs.'' The purpose of the public meeting is to
discuss perspectives from interested parties on increasing access to
nonprescription drugs. We are also requesting comments.
DATES: The public meeting will be held virtually and in person on April
23, 2026, from 12:30 p.m. to 5 p.m. Eastern Time. Either electronic or
written comments on this public meeting must be submitted by May 8,
2026. See the SUPPLEMENTARY INFORMATION section for registration date
and information.
ADDRESSES: The public meeting will be held virtually using the Zoom
platform and in person at the National Press Club, 529 14th Street NW,
Washington, DC 20045, with limited seat availability.
You may submit comments as follows. Please note that late, untimely
filed comments will not be considered. The <a href="https://www.regulations.gov">https://www.regulations.gov</a>
electronic filing system will accept comments until 11:59 p.m. Eastern
Time at the end of May 8, 2026. Comments received by mail/hand
delivery/courier (for written/paper submissions) will be considered
timely if they are received on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
<bullet> Federal eRulemaking Portal: <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to <a href="https://www.regulations.gov">https://www.regulations.gov</a>
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
<bullet> If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
<bullet> Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
<bullet> For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2025-N-4731 for ``Increasing
[[Page 20171]]
Availability of Nonprescription Drugs; Public Meeting; Request for
Comments.'' Received comments, those filed in a timely manner (see
ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at <a href="https://www.regulations.gov">https://www.regulations.gov</a> or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday, 240-402-7500.
<bullet> Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: <a href="https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf">https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf</a>.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT: Phong Pham, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 22, Rm. 6122, Silver Spring, MD 20993-0002, 301-837-7656,
<a href="/cdn-cgi/l/email-protection#5101393e3f367f0139303c113735307f3939227f363e27"><span class="__cf_email__" data-cfemail="53033b3c3d347d033b323e133537327d3b3b207d343c25">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
I. Background
In connection with the Federal Register notice entitled
``Increasing Access to Nonprescription Drugs; Request for
Information,'' published December 2, 2025 (90 FR 55316) (the December
2025 notice), we are announcing a public meeting to discuss topics
related to increasing access to nonprescription drugs. This public
meeting will be convened and supported by a cooperative agreement
between FDA and the Duke-Margolis Institute for Health Policy. We also
welcome any comments on specific topics covered at the public meeting
or about increasing access to nonprescription drugs generally. If you
submitted a comment to the December 2025 notice, you do not need to
resubmit it here.
II. Participating in the Public Meeting
Registration: To register for the public meeting, please visit the
event website: <a href="https://duke.is/p/4g3b">https://duke.is/p/4g3b</a>.
Registration is free and based on space availability, with priority
given to early registrants. Persons interested in attending this public
meeting in person must register by April 22, 2026, at 5 p.m. Eastern
Time and receive registration confirmation. Early registration is
recommended because seating is limited. Persons attending virtually
must register by April 23, 2026, at 5 p.m. Eastern Time. Registrants
will receive confirmation when they have been accepted. If you need
special accommodations due to a disability, please contact
<a href="/cdn-cgi/l/email-protection#c7aaa6b5a0a8abaeb4a2b1a2a9b3b487a3b2aca2e9a2a3b2"><span class="__cf_email__" data-cfemail="e18c8093868e8d88928497848f9592a185948a84cf848594">[email protected]</span></a> no later than April 22, 2026, at 5 p.m. Eastern
Time.
Streaming Webcast of the Public Meeting: This public meeting will
also be webcast via Zoom. The archived footage will be available at the
event website: <a href="https://duke.is/p/4g3b">https://duke.is/p/4g3b</a>.
Transcripts: A link to the transcript will be available on the
internet at <a href="https://duke.is/p/4g3b">https://duke.is/p/4g3b</a>.
Notice of this meeting is given pursuant to 21 CFR 10.65.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2026-07335 Filed 4-14-26; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js" defer></script></body>
</html>Indexed from Federal Register on April 15, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.